#ASH18: BeiGene works to bust through the check­point crowd with a piv­otal read­out that proves its PD-1 is bet­ter than the rest

With 2 pi­o­neer­ing PD-1s lord­ing it over the 6 ap­proved check­points in its class, what dif­fer­ence can 1 more make?

The ex­ec­u­tive team at BeiGene is glad you asked.

On Mon­day, the Chi­nese biotech post­ed some re­mark­able re­sults for their piv­otal study aimed at gain­ing a quick OK in Chi­na for their PD-1 tislelizum­ab in treat­ment-re­sis­tant clas­si­cal Hodgkin’s lym­phoma. And they’re tak­ing their best shot at mak­ing a case in San Diego that this one could be sig­nif­i­cant­ly bet­ter than its many ri­vals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER